.@genetexinc your resource, https://t.co/IS9FjgiGt1, was just reported to be used in "CANCER-ASSOCIATED SF3B1 MUTATIONS CONFER A BRCA-LI…": https://t.co/lh0JGxO8rU (https://t.co/QsXooAHvLh). We appreciate the author's support of reproducibility. #RRID #acc
RT @CR_AACR: The cancer-associated SF3B1K700E mutation induces increased #DNADamage that affects #HomologousRecombination. This causes incr…
RT @CR_AACR: The cancer-associated SF3B1K700E mutation induces increased #DNADamage that affects #HomologousRecombination. This causes incr…
The cancer-associated SF3B1K700E mutation induces increased #DNADamage that affects #HomologousRecombination. This causes increased sensitivity to radiation and chemotherapeutic agents and induces a BRCA-like cellular phenotype. https://t.co/ZFhuw8fqzW htt
RT @unibirm_MDS: A defective gene normally found in #BloodCancers could be treated with drugs already available for cancers with similar ge…
A defective gene normally found in #BloodCancers could be treated with drugs already available for cancers with similar gene defects, scientists within @IcgsUob, @unibirmingham and @QUBelfast have revealed: https://t.co/kKOmwbYltS
A recent study published in Cancer Research has found that a defective gene normally found in blood cancers could be treated with drugs already available for cancers with similar gene defects. @GS_Lab_Bham @QUBelfast @CR_UK @The_MRC. Read more: https://t.c
Great work by my new supervisor and the rest of the team! #CancerResearch
RT @LAL_NI: Great to see LLNI funded researchers involved in the publication of an exciting study in to new treatments for SF3B1 mutant can…
RT @LAL_NI: Great to see LLNI funded researchers involved in the publication of an exciting study in to new treatments for SF3B1 mutant can…
Great to see LLNI funded researchers involved in the publication of an exciting study in to new treatments for SF3B1 mutant cancers. Well done to all invovled. https://t.co/eli5Sj2D1Y https://t.co/lqzfux5mZv
CANCER-ASSOCIATED SF3B1 MUTATIONS CONFER A BRCA-LIKE CELLULAR PHENOTYPE AND SYNTHETIC LETHALITY TO PARP INHIBITORS https://t.co/QBVb0yv8xq
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
CANCER-ASSOCIATED SF3B1 MUTATIONS CONFER A BRCA-LIKE CELLULAR PHENOTYPE AND SYNTHETIC LETHALITY TO PARP INHIBITORS https://t.co/8lYIg2JsvT
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
Very cool. The ever increasing number of genomic, metabolic, and other tumor alterations that confer synthetic lethality to PARP inhibitors is quite amazing 🧐
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
RT @GS_Lab_Bham: Congratulations to the Savage lab @KienanSavage @katrina_lappin on their recent publication in Cancer Research @CR_AACR on…
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
Congratulation Kienan and team!
Happy to announce (and be part of) a study by @katrina_lappin from the Savage lab & Stewart lab (@KienanSavage & @GS_Lab_Bham ) describing how SF3B1 mutations give rise to a BRCA-like phenotype & synthetic lethality to PARP inhibitors! https:/
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
RT @GS_Lab_Bham: Congratulations to the Savage lab @KienanSavage @katrina_lappin on their recent publication in Cancer Research @CR_AACR on…
RT @KienanSavage: Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s…
Great to be part of this exciting study led by @KienanSavage with 1st author @katrina_lappin
Very happy to see our work describing how SF3B1 mutations confer a BRCA-like phenotype and synthetic lethality to PARPi’s, published in @CR_AACR suggesting new treatments for SF3B1 mutant cancers. https://t.co/KB5Zs6tuQk @QubPGJCCR @QUBBloodCancer @CR_UK
Congratulations to the Savage lab @KienanSavage @katrina_lappin on their recent publication in Cancer Research @CR_AACR on identifying a synthetic lethal interaction between SF3B1 mutations and PARPi. Glad that the Stewart lab could be a part of it. https